Glenmark's molecule for pain therapy entering human trials

Glenmark Pharmaceuticals today said its novel chemical entity for potential treatment of chronic inflammatory disorders is entering human trials.

Glenmark has completed preclinical studies and Phase 1 enabling good laboratory practise for the molecule, GRC 27864, and has filed a Phase 1 application for first-in-human trial with the MHRA, UK, Glenmark Pharma said in a BSE filing.

The Phase 1 studies are to be initiated soon and are likely to get completed by January 2015, it added.

Glenmark Pharmaceuticals Ltd Chief Scientific Officer Michael Buschle said: "This is another first-in-class molecule and there is a significant unmet medical need. This announcement also reaffirms our position globally in the development of novel pain therapies."

Indicating potential and size of the market for the drug, the firm said: " 20% of the global adult population suffers from pain with 10% of newly diagnosed cases of chronic pain cases being added every year."

Following human trial, Glenmark will initiate a proof of concept study in patients with acute pain.

EDITORIAL OF THE DAY

  • India’s political space acts as a safety valve for maverick politicians and frustrated electorate

    While it is easy to be cynical about Indian democracy and its ways, the fact is that the vast political space that the system provides for in this cou

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Taslima Nasreen

Bangladesh no country for atheists

It’s a matter of pride to be a freethinker, atheist ...

Purnendu Ghosh

Silence makes you aware of yourself

Often, we don’t feel the necessity of making contact with ...

Shona Adhikari

Artistic focus on women's empowerment

The focus on the girl child remains an important one ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture